Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Cutaneous & Mucosal Melanoma — Options & Clinical Trial Reference
Source-cited reference covering BRAF V600 status, NRAS/KIT, nodal staging, neoadjuvant/adjuvant and checkpoint/targeted therapy categories, and recruiting trials.
Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesbiomarkers
versionstatuspending_status_valuesbiomarkers
Unranked Guideline & FDA-Label Option Categories (36 total)
| Option / Pathway | Category | Primary Sources |
|---|---|---|
| Surgery and regional-node staging review | Local care | nci-melanoma, nci-melanoma-pdq-2025 |
| Post-resection surveillance discussion | Follow-up | nci-melanoma |
| Adjuvant pembrolizumab | Systemic therapy | keytruda-label, keynote716, kn716-final, kn054-7y |
| Adjuvant nivolumab | Systemic therapy | opdivo-label, checkmate76k, checkmate238, cm76k-primary, cm238-9y, cm238-correction |
| Adjuvant dabrafenib plus trametinib | Systemic therapy | tafinlar-label, mekinist-spl, combiad-final |
| Review discordant adjuvant BRAF V600K evidence | Specialist review | tafinlar-label, combiad-final |
| Neoadjuvant nivolumab plus ipilimumab, then response-guided review | Systemic therapy | nadina, opdivo-label |
| Perioperative pembrolizumab | Systemic therapy | s1801, keytruda-label |
| Upfront surgery followed by adjuvant-treatment review | Local care | nci-melanoma, nadina, s1801 |
| Nivolumab plus ipilimumab | Systemic therapy | opdivo-label, checkmate067-final, dreamseq, nct01844505 |
| Nivolumab plus relatlimab | Systemic therapy | opdualag-label, relativity047 |
| Nivolumab monotherapy | Systemic therapy | opdivo-label, checkmate067-final, relativity047, nct01844505 |
| Pembrolizumab monotherapy | Systemic therapy | keytruda-label, kn006-10y, nct01866319 |
| Dabrafenib plus trametinib | Systemic therapy | tafinlar-label, mekinist-spl, dreamseq |
| Encorafenib plus binimetinib | Systemic therapy | mektovi-label, braftovi-spl, mektovi-spl, columbus-7y |
View all 36 Cutaneous & Mucosal Melanoma reference options →
Recruiting Clinical Trials (32 curated)
| NCT ID | Study Title | Phase |
|---|---|---|
| NCT01638676 | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | PHASE1/PHASE2 |
| NCT02621021 | A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | PHASE2 |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | PHASE1/PHASE2 |
| NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | PHASE3 |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | PHASE2 |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | PHASE1/PHASE2 |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | PHASE1 |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | PHASE2 |
| NCT04594187 | Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | PHASE2 |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | PHASE1/PHASE2 |
| NCT04844528 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers | PHASE2 |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | PHASE1/PHASE2 |